Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Genome-Wide Association Studies as a Diagnostic Test to Predict Susceptibility to Cisplatin-Induced Hearing Loss
EF 2009-10
Résumé
Each year a significant number of deaths and hospitalizations result from adverse drug reactions (ADRs) ranking it as the fifth leading cause of death. Children are especially at risk of ADRs, given that less than 25% of approved pharmaceuticals have been tested in children resulting in inadequate guidelines for safety and efficacy in this population.
Cisplatin is a widely used, effective chemotherapeutic agent for treatment of solid tumours in both adults and children. A major drawback that limits its clinical use is the severe permanent hearing loss in 10-25% of adults and 41-61% of children. Some patients tolerate high doses of the drug without any problems while others develop severe hearing loss, even at very low doses.
Although there are many factors that contribute to a patient's response to therapy, genetic factors are said to account for a significant proportion of drug response variability and are estimated to play a role in at least half of all ADRs. The goal of the proposed research is to identify genetic factors that confer susceptibility to cisplatin-induced hearing loss in order to develop predictive diagnostic tests that can be used to prevent this ADR.
Various enzymes and transport systems are involved in drug metabolism. By identifying genetic markers that regulate these processes, it would be possible to identify patients at risk of toxicity prior to therapy to reduce the incidence of these ADRs. We will screen for genetic variants in children who have received cisplatin and experienced hearing loss, and compare these with children who have also received cisplatin without experiencing hearing loss.
This research will lead to new information about how differences in genetic factors can predispose people to severe ADRs. This will ultimately lead to the development of a safe dosing guideline based on a patient's genetic profile to prevent potentially severe ADRs from occurring.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
201555
Name
Pussegoda Kusala A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Genome-Wide Association Studies as a Diagnostic Test to Predict Susceptibility to Cisplatin-Induced Hearing Loss
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Drug Reactions; Cancer; Pharmacogenomics
Abstract
Each year a significant number of deaths and hospitalizations result from adverse drug reactions (ADRs) ranking it as the fifth leading cause of death. Children are especially at risk of ADRs, given that less than 25% of approved pharmaceuticals have been tested in children resulting in inadequate guidelines for safety and efficacy in this population.
Cisplatin is a widely used, effective chemotherapeutic agent for treatment of solid tumours in both adults and children. A major drawback that limits its clinical use is the severe permanent hearing loss in 10-25% of adults and 41-61% of children. Some patients tolerate high doses of the drug without any problems while others develop severe hearing loss, even at very low doses.
Although there are many factors that contribute to a patient's response to therapy, genetic factors are said to account for a significant proportion of drug response variability and are estimated to play a role in at least half of all ADRs. The goal of the proposed research is to identify genetic factors that confer susceptibility to cisplatin-induced hearing loss in order to develop predictive diagnostic tests that can be used to prevent this ADR.
Various enzymes and transport systems are involved in drug metabolism. By identifying genetic markers that regulate these processes, it would be possible to identify patients at risk of toxicity prior to therapy to reduce the incidence of these ADRs. We will screen for genetic variants in children who have received cisplatin and experienced hearing loss, and compare these with children who have also received cisplatin without experiencing hearing loss.
This research will lead to new information about how differences in genetic factors can predispose people to severe ADRs. This will ultimately lead to the development of a safe dosing guideline based on a patient's genetic profile to prevent potentially severe ADRs from occurring.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pussegoda, Kusala A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~